Reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-29 and is reviewed periodically as new material appears.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
=== Thiol-carboxylic acids === Cysteine and penicillamine have the formula HSCR2CH(NH2)CO2H, where R = H and CH3, respectively. Cysteine is common amino acid, and penicillamine has medicinal properties. Coenzyme A and glutathione are more complicated thiol-containing derivatives. Cysteine-rich proteins called metallothionein have high affinity for heavy metals. Thiocarboxylic acids, with the formula HS(O)CR, can be considered thiols also. Thioacetic acid is one example.
== Metabolism == A cytochrome P450 enzyme is proposed to metabolize diethyl ether. Diethyl ether inhibits alcohol dehydrogenase, and thus slows the metabolism of ethanol. It also inhibits metabolism of other drugs requiring oxidative metabolism. For example, diazepam requires hepatic oxidization whereas its oxidized metabolite oxazepam does not.
== Low-energy CID and high-energy CID == Low-energy CID is typically carried out with ion kinetic energies less than approximately 1 kiloelectron volt (1 keV). Low-energy CID is highly efficient in fragmenting the selected precursor ions, but the type of fragment ions observed in low-energy CID is strongly dependent on the ion kinetic energy. Very low collision energies favor ion structure rearrangement, and the probability of direct bond cleavage increases as ion kinetic energy increases, leading to higher ion internal energies. High-energy CID (HECID) is carried out in magnetic sector mass spectrometers or tandem magnetic sector mass spectrometers and in tandem time-of-flight mass spectrometers (TOF/TOF). High-energy CID involves ion kinetic energies in the kilovolt range (typically 1 keV to 20 keV). High-energy CID can produce some types of fragment ions that are not formed in low-energy CID, such as charge-remote fragmentation in molecules with hydrocarbon substructures or sidechain fragmentation in peptides.
Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate, a prodrug of dexmethylphenidate, and dexmethylphenidate, a d-threo enantiomer of racemic methylphenidate, which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older. Side effects include decreased appetite, nausea, indigestion, weight loss, dizziness, mood swings, increased blood pressure, trouble sleeping, vomiting, stomach pain, anxiety, irritability, and increased heart rate. It was approved for medical use in the United States in March 2021.
=== April === 1 April Biochemists report finishing the complete sequence of the human genome. A study shows that, contrary to widespread belief, body sizes of mammal extinction survivors of the dinosaur-times extinction event were the first to evolutionarily increase, with brain sizes increasing later in the Eocene. 4 April The Intergovernmental Panel on Climate Change (IPCC) releases the third and final part of its Sixth Assessment Report on climate change, warning that greenhouse gas emissions must peak before 2025 at the latest and decline 43% by 2030, in order to likely limit global warming to 1.5 °C (2.7 °F). Researchers announce a new technique for accelerating the development of vaccines and other pharmaceutical products by up to a million times, using much smaller quantities based on DNA nanotechnology. Alzheimer's disease (AD) research progress:A study reports 42 new genes linked to an increased risk of AD. Researchers report a potential primary mechanism of sleep disturbance as an early-stage effect of neurodegenerative diseases. Researchers identify several genes associated with changes in brain structure over lifetime and potential AD therapy-targets (5 Apr).
Sources: en.wikipedia.org
== Cause == A diagnosis of iron-deficiency anemia requires further investigation into its cause. It can be caused by increased iron demand, increased iron loss, or decreased iron intake. Increased iron demand often occurs during periods of growth, such as in children and pregnant women. For example, during stages of rapid growth, babies and adolescents may outpace their dietary intake of iron, which can result in deficiency in the absence of disease or a grossly abnormal diet. Iron loss is typically from blood loss. One example of blood loss is by chronic gastrointestinal blood loss, which could be linked to a possible cancer. In women of childbearing age, heavy menstrual periods can be a source of blood loss, causing iron-deficiency anemia. People who do not consume much iron in their diet, such as vegans or vegetarians, are also at increased risk of developing iron deficiency anemia.
The US and the USSR sent animals into space to determine the safety of the environment before sending the first humans. The USSR used dogs for this purpose, and the US used monkeys and apes. The first mammal in space was Albert II, a rhesus monkey launched by the US on a sub-orbital flight on June 14, 1949, who died on landing due to a parachute malfunction. The USSR sent the dog Laika into orbit on Sputnik 2, the second satellite launched, on November 3, 1957, for an intended ten-day flight. They did not yet have the technology to return Laika safely to Earth, and the government reported Laika died when the oxygen ran out, but in October 2002 her true cause of death was reported as stress and overheating on the fourth orbit due to failure of the air conditioning system. At a Moscow press conference in 1998 Oleg Gazenko, a senior Soviet scientist involved in the project, stated "The more time passes, the more I'm sorry about it. We did not learn enough from the mission to justify the death of the dog...".
Although francium is the heaviest alkali metal that has been discovered, there has been some theoretical work predicting the physical and chemical characteristics of hypothetical heavier alkali metals. Being the first period 8 element, the undiscovered element ununennium (element 119) is predicted to be the next alkali metal after francium and behave much like their lighter congeners; however, it is also predicted to differ from the lighter alkali metals in some properties. Its chemistry is predicted to be closer to that of potassium or rubidium instead of caesium or francium. This is unusual as periodic trends, ignoring relativistic effects would predict ununennium to be even more reactive than caesium and francium. This lowered reactivity is due to the relativistic stabilisation of ununennium's valence electron, increasing ununennium's first ionisation energy and decreasing the metallic and ionic radii; this effect is already seen for francium. This assumes that ununennium will behave chemically as an alkali metal, which, although likely, may not be true due to relativistic effects. The relativistic stabilisation of the 8s orbital also increases ununennium's electron affinity far beyond that of caesium and francium; indeed, ununennium is expected to have an electron affinity higher than all the alkali metals lighter than it. Relativistic effects also cause a very large drop in the polarisability of ununennium.
Numerous artists and writers living in France in the late 19th and early 20th centuries were noted absinthe drinkers and featured absinthe in their work. Some of these included Édouard Manet, Guy de Maupassant, Paul Verlaine, Amedeo Modigliani, Edgar Degas, Henri de Toulouse-Lautrec, Vincent van Gogh, Oscar Wilde, Arthur Rimbaud, and Émile Zola. Many other renowned artists and writers similarly drew from this cultural well, including Aleister Crowley, Ernest Hemingway, Pablo Picasso, August Strindberg, and Erik Satie. The aura of illicitness and mystery surrounding absinthe has played into literature, movies, music, and television, where it is often portrayed as a mysterious, addictive, and mind-altering drink. Marie Corelli's Wormwood: A Drama of Paris (1890) was a popular novel about a Frenchman driven to murder and ruin after being introduced to absinthe. Intended as a morality tale on the dangers of the drink, it was speculated to have contributed to subsequent bans of absinthe in Europe and the United States. Some of the earliest film references include The Hasher's Delirium (1910) by Émile Cohl, an early pioneer in the art of animation, as well as two different silent films, each titled Absinthe, from 1913 and 1914 respectively. More recently, it served as the title of a 2018 song by the indie group I Don't Know How But They Found Me.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.